Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.

Ohba, Tetsuro; Cole, Heather A; Cates, Justin M M; Slosky, David A; Haro, Hirotaka; Ando, Takashi; Schwartz, Herbert S; Schoenecker, Jonathan G

Ohba, Tetsuro; Cole, Heather A; Cates, Justin M M; Slosky, David A; Haro, Hirotaka; Ando, Takashi; Schwartz, Herbert S; Schoenecker, Jonathan G.

Affiliation

Ohba T; Department of Orthopaedics, Vanderbilt University Medical Center, Nashville, TN, USA.

J Bone Miner Res ; 29(6): 1431-45, 2014 Jun.

Article in En | MEDLINE | ID: mdl-24443409

Subject(s)

Chemokine CCL2/metabolism; Diphosphonates/therapeutic use; Osteolysis/drug therapy; Osteolysis/etiology; Osteosarcoma/complications; RANK Ligand/metabolism; Animals; Bone Resorption/pathology; Cell Differentiation/drug effects; Cell Line, Tumor; Cell Proliferation/drug effects; Chemokine CCL2/blood; Diphosphonates/pharmacology; Humans; Imidazoles/pharmacology; Imidazoles/therapeutic use; Mice; Monocytes/drug effects; Monocytes/metabolism; Neoplasm Invasiveness; Osteoclasts/drug effects; Osteoclasts/metabolism; Osteoclasts/pathology; Osteogenesis/drug effects; Osteolysis/blood; Osteolysis/physiopathology; Osteoprotegerin/metabolism; Osteosarcoma/blood; Osteosarcoma/pathology; Osteosarcoma/physiopathology; Zoledronic Acid

Key words

BISPHOSPHONATES; MCP-1; OSTEOCLAST; OSTEOSARCOMA; RANKL/OPG

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Osteolysis / Osteosarcoma / Chemokine CCL2 / Diphosphonates / RANK Ligand Type of study: Clinical_trials Limits: Animals / Humans Language: En Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google